KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Castle Biosciences (CSTL) Net Income towards Common Stockholders: 2018-2025

Historic Net Income towards Common Stockholders for Castle Biosciences (CSTL) over the last 8 years, with Sep 2025 value amounting to -$501,000.

  • Castle Biosciences' Net Income towards Common Stockholders fell 122.08% to -$501,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.2 million, marking a year-over-year decrease of 300.86%. This contributed to the annual value of $18.2 million for FY2024, which is 131.75% up from last year.
  • Latest data reveals that Castle Biosciences reported Net Income towards Common Stockholders of -$501,000 as of Q3 2025, which was down 110.99% from $4.6 million recorded in Q2 2025.
  • In the past 5 years, Castle Biosciences' Net Income towards Common Stockholders ranged from a high of $9.6 million in Q4 2024 and a low of -$29.2 million during Q1 2023.
  • Its 3-year average for Net Income towards Common Stockholders is -$5.5 million, with a median of -$2.5 million in 2024.
  • As far as peak fluctuations go, Castle Biosciences' Net Income towards Common Stockholders slumped by 1,039.38% in 2023, and later skyrocketed by 471.71% in 2024.
  • Quarterly analysis of 5 years shows Castle Biosciences' Net Income towards Common Stockholders stood at -$6.4 million in 2021, then tumbled by 220.65% to -$20.6 million in 2022, then surged by 87.49% to -$2.6 million in 2023, then skyrocketed by 471.71% to $9.6 million in 2024, then slumped by 122.08% to -$501,000 in 2025.
  • Its last three reported values are -$501,000 in Q3 2025, $4.6 million for Q2 2025, and -$25.8 million during Q1 2025.